Endoscopic Medical Devices for Primary Obesity Treatment in Patients With Diabetes.

about

Erratum: Endoscopic Medical Devices for Primary Obesity Treatment in Patients With Diabetes. Diabetes Spectrum 2017;30;258-264 (DOI:10.2337/ds017-0046).

P921

Q49850914-AA764C4C-9C4A-4D64-9B26-86CEDF6E14BF

P921

Endoscopic Medical Devices for Primary Obesity Treatment in Patients With Diabetes.

Item

http://www.wikidata.org/entity/Q49899718

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Endoscopic Medical Devices for Primary Obesity Treatment in Patients With Diabetes.

@en

Endoscopic Medical Devices for Primary Obesity Treatment in Patients With Diabetes.

@nl

type

Item

label

Endoscopic Medical Devices for Primary Obesity Treatment in Patients With Diabetes.

@en

Endoscopic Medical Devices for Primary Obesity Treatment in Patients With Diabetes.

@nl

prefLabel

Endoscopic Medical Devices for Primary Obesity Treatment in Patients With Diabetes.

@en

Endoscopic Medical Devices for Primary Obesity Treatment in Patients With Diabetes.

@nl

P1476

Endoscopic Medical Devices for Primary Obesity Treatment in Patients With Diabetes.

@en

P2093

Shelby Sullivan

http://www.w3.org/2001/XMLSchema#string

P2507

Erratum: Endoscopic Medical Devices for Primary Obesity Treatment in Patients With Diabetes. Diabetes Spectrum 2017;30;258-264 (DOI:10.2337/ds017-0046).

P2860

ASGE Bariatric Endoscopy Task Force systematic review and meta-analysis assessing the ASGE PIVI thresholds for adopting endoscopic bariatric therapies.

Human duodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIP.

Aspiration therapy leads to weight loss in obese subjects: a pilot study.

The REDUCE pivotal trial: a prospective, randomized controlled pivotal trial of a dual intragastric balloon for the treatment of obesity.

Jejunal proteins secreted by db/db mice or insulin-resistant humans impair the insulin signaling and determine insulin resistance

Aspiration therapy for obesity; a safe and effective treatment

Glucose sensing by gut endocrine cells and activation of the vagal afferent pathway is impaired in a rodent model of type 2 diabetes mellitus

Percutaneous Gastrostomy Device for the Treatment of Class II and Class III Obesity: Results of a Randomized Controlled Trial.

ASGE Technology Committee systematic review and meta-analysis assessing the ASGE PIVI thresholds for adopting real-time endoscopic assessment of the histology of diminutive colorectal polyps.

MILEPOST Multicenter Randomized Controlled Trial: 12-Month Weight Loss and Satiety Outcomes After pose SM vs. Medical Therapy.

P304

258-264

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2337/DS017-0046

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29151716

http://www.w3.org/2001/XMLSchema#string

P932

5687104

http://www.w3.org/2001/XMLSchema#string

Endoscopic Medical Devices for Primary Obesity Treatment in Patients With Diabetes.

about

P921

P921

Endoscopic Medical Devices for Primary Obesity Treatment in Patients With Diabetes.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2507

P2860

P304

P31

P356

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2507

P2860

P304

P31

P356

P433

P478

P577

P698

P932